{
}
UBS has initiated coverage of Alvotech (ICSE:ALVO) with a Buy recommendation, projecting a 58.60% upside based on an average one-year price target of ISK2,838.88 per share. The company is expected to see an 85.21% increase in annual revenue, reaching 730MM, with a projected non-GAAP EPS of 0.93. Institutional ownership has risen by 18% in the last quarter, despite a 6.38% decrease in total shares owned.
Market analysts have identified five stocks as top buys, excluding Alvotech, which holds a "Buy" rating with a price target of $18.00 from UBS Group, indicating a potential upside of 40.85%. Alvotech specializes in developing biosimilar medicines for various conditions, with recent institutional investments totaling over $1 million.
UBS has reiterated its Buy recommendation for Alvotech SA (NASDAQ: ALVO) with a target price of $18, indicating a 41% upside from the current price of $13.03. The company, which has seen significant revenue growth, is projected to reach $1.6 billion in sales by 2028, driven by its expanding biosimilar pipeline and successful product launches. Alvotech aims to maintain a revenue guidance of $400 million to $500 million for 2024 and $600 million to $800 million for 2025, despite some uncertainties in product shipments.
Alvotech has received a Buy rating from UBS, signaling positive market sentiment towards the company. This recommendation highlights the potential for growth and investment opportunities in Alvotech's future.
Alvotech
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs initiates buy recommendation for alvotech with significant price upside potential
03:21 16.02.2025
analysts recommend five stocks over alvotech despite its buy rating
15:21 15.02.2025
ubs maintains buy rating for alvotech shares with strong growth potential
17:58 14.02.2025
Alvotech receives buy rating from UBS according to TipRanks
13:20 14.02.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Banking Regulations
Global Financial Events
Market Analysis and Predictions
Financial Scams and Security
Retail and Consumer Goods
CEO Changes
Central Bank Actions
Global Trade Developments
GDP Growth & Recession Forecasts
Industry Mergers & Acquisitions
Hedge Funds & Private Equity
Government Policies
Inflation and Monetary Impact
Workplace Trends
Startups & Entrepreneurship
Government Economic Policies
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Bank of America Corporation
Apple Inc.
Wells Fargo & Company
Citigroup Inc.
Barclays PLC
Morgan Stanley
Lloyds Banking Group plc
Huawei Technologies CO. Ltd.
Deutsche Bank Money Market PP
American Express Company
UBS Group AG
AMERICAN EXPRESS
Northern Trust Corporation
Berkshire Hathaway Inc.
Credit Suisse Strategic Income I
AXA SA
Safran SA
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Canadian Dollar
Australian Dollar
Russian Ruble
Saudi Riyal
United Arab Emirates Dirham
Indonesian Rupiah
Hong Kong Dollar
Offshore Chinese Yuan
Singapore Dollar
Ghanaian Cedi
Mexican Peso
South Korean Won
Danish Krone
People:
Donald Trump
Elon Musk
Michael J. Angelakis
Goldman Sachs
Troy L Rohrbaugh
Charlie Javice
Warren Buffett
Sara Wechter
Brad Schimel
Olivier Amar
Robin Leopold
Jennifer Piepszak
Anand Selvakesari
Jerome Powell
Mark Mason
Susan P. Crawford
Will Hardcastle
Karin Keller-Sutter
Stacey Friedman
Sabrina Meng